What is FK228?

What is FK228?

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Is romidepsin FDA approved?

In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the U.S. Food & Drug Administration (FDA) for Istodax® (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who …

Who manufactures romidepsin?

Romidepsin is branded and owned by Gloucester Pharmaceuticals, now a part of Celgene.

Is istodax chemo?

Istodax® is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.

How common is cutaneous T-cell lymphoma?

CTCL is a rare form of T-cell lymphoma. There are about 3,000 new cases of CTCL in the U.S. each year, and about 16,000 – 20,000 Americans have mycosis fungoides.

Is romidepsin a chemotherapy?

Drug Type: Romidepsin is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. Romidepsin is classified as a “Histone Deacetylase Inhibitor”-for more detail, see “How this drug works,” below).

How is romidepsin supplied?

ISTODAX (romidepsin) for injection is a sterile lyophilized white powder and is supplied in a single-use vial containing 10 mg romidepsin and 20 mg povidone, USP. Diluent for ISTODAX is a sterile clear solution and is supplied in a single-use vial containing a 2-mL deliverable volume.

What is end stage chemotherapy?

The study found that a majority of the end-stage cancer patients it examined received so-called palliative chemotherapy; oncologists widely assume that in these patients, whose remaining life expectancy is six months or less, that the treatment eases symptoms and extends survival.

Does romidepsin cause hair loss?

Hair loss does not occur with romidepsin.